Privia Health (NASDAQ:PRVA) posts better-than-expected sales in Q3 2026, guides for strong full-year sales
Privia Health (PRVA) reported Q3 2026 revenue of $657M, beating estimates by 7.5% and growing 13.2% YoY. Adjusted EPS missed estimates by 11.8%, while adjusted EBITDA beat by 4%. Full-year EBITDA guidance was raised above consensus. Sales volumes grew 12.2% YoY, consistent with prior year.
How this was made
The 30-second read
Why it matters
The earnings beat on revenue and raised guidance could attract buying interest, while the EPS miss may cause some sellers to target the stock.
Market read
First earnings release for Q3 2026 with mixed results; provides a clear short-term trading catalyst.
What to watch
Guidance beat could offset EPS miss if the market focuses on top-line growth.
Background
Privia Health is a provider of technology-enabled outpatient services and revenue growth reflects its expanding client base.
Ticker impact
Privia Health reported Q3 2026 revenue of $657M beating estimates and raised full-year EBITDA guidance above consensus.
likely modest pressure as market weighs EPS miss against revenue beat and higher guidance
The mixed earnings surprise (revenue beat, EPS miss) and upgraded full-year EBITDA guidance provide a clear catalyst for short-term price movement.
Market effects
Positive for healthcare services sector as revenue beat may signal demand strength.
Limited to US healthcare market.
Low global impact.
Counterpoint
Investors may view the EPS miss as a sign of margin pressure despite revenue growth.
Key entities
- CompanyPrivia Health
US-listed healthcare services provider (NASDAQ:PRVA).
